Acorda CEO Cohen throws his weight behind new biotech trailblazer

When I first met Acorda CEO Ron Cohen, the company's lead drug--Ampyra--was still in clinical development at its headquarters in Westchester County, NY. And even then he was quick to tout the area's potential as an emerging biotech hub--something that has been much discussed but always remained elusive.  

The CEO is still a true believer the region. And now Cohen is helping spearhead a new biotech economic development group to highlight the potential of the Hudson Valley area; recruiting new biotechs to the area, linking up with venture organizations and pushing its own legislative agenda.

"Acorda has been based in the Hudson Valley for over a decade and we are proud to have contributed to building a vibrant biotechnology community in the area," he said in a release out today. "In collaboration with its founding members, NY BioHud Valley will be an important voice in attracting a broad range of high quality biotech companies and skilled professionals to this region to support the continued growth of the Hudson Valley biotechnology corridor."

- read the Acorda release

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.